ライフサイエンスコーパス: injectable

1 consistent administration of the long-acting injectable.

2 ant to fluoroquinolones (Fqs) or second-line injectables.

3 automated productions provided 34 +/- 2% of injectable [(18)F]7 from up to 285 GBq (7.7 Ci) of [(18)

4 This novel intratumorally injectable (198)AuNP-EGCg nanotherapeutic agent may prov

5 Injectable 3D scaffolds, in the form of elastic sponge-l

6 ST for both fluoroquinolones and second-line injectable: 55.8% (466 of 835) in the Western Cape and 2

7 ermit reliable and high-yield preparation of injectable (68)Ga-DOTATOC (or other (68)Ga-labeled radio

8 Injectable, acellular biomaterials hold promise to limit

9 The maximum-injectable activity (MIA) for tolerance criteria based o

10 In multivariable Cox models, neither injectable (adjusted hazard ratio [aHR], 0.6; 95% CI, .4

11 ent plan including training updates for self-injectable adrenaline and nasal spray use.

12 For question 2, first-line injectable agents (ampicillin, gentamicin, and penicilli

13 bladder neck may be improved with the use of injectable agents.

14 dy, we show for the first time the use of an injectable alginate hydrogel for controlled delivery of

15 erall, we find that NDs provide an effective injectable alternative for the delivery of BMP-2 and bFG

16 isoniazid, rifampicin, fluoroquinolones and injectable aminoglycosides, they would be suitable for t

17 These injectable analogs achieve robust glycemic control by in

18 ely effective drugs (including a second-line injectable and a fluoroquinolone) used for at least 6 mo

19 A brief outlook on the future of injectable and biodegradable hydrogels is also presented

20 The injectable and biodegradable hydrogels were prepared by

21 hibition is achievable through the use of an injectable and bioresponsive hydrogel.

22 These injectable and moldable colloidal gels are able to withs

23 In our previous study, we have developed an injectable and porous nano calcium sulfate/alginate (nCS

24 bone reconstruction system consisting of an injectable and porous nCS/A scaffold (mimicking the nano

25 , we hypothesized that the combination of an injectable and porous nCS/A with bone morphogenetic prot

26 ndly alternative to currently marketed GLP-1 injectables and can likely be extended to other peptide

27 ged from 1.7 to 2.3, whereas for second-line injectables and fluoroquinolones, odds ranged from 2.4 t

28 t optimizing the dosing of pyrazinamide, the injectables, and isoniazid for drug-resistant tuberculos

29 ht, all reported findings for progestin-only injectables, and seven also reported findings for oral c

30 und that a single in vivo treatment with the injectable anesthetic etomidate increased a tonic inhibi

31 The injectable anti-IgE therapy omalizumab has been shown to

32 ment is hospital admission with 7-10 days of injectable antibiotic therapy.

33 Availability of first-line injectable antibiotics appears low in many health facili

34 antibiotic regimens with reduced numbers of injectable antibiotics combined with oral antibiotics ha

35 n monthly costs for a cohort of 24 patented, injectable anticancer drugs that were approved by the US

36 e, in a cyanide disaster, intramuscular (IM) injectable antidotes would be more appropriate.

37 s are well suited for further development as injectable antifibrinolytic drugs.

38 0.58; 95% CI, 0.53-0.63) and all long-acting injectable antipsychotic medications (HRs 0.65-0.80) wer

39 Long-acting injectable antipsychotic medications were associated wit

40 Clozapine and long-acting injectable antipsychotic medications were the pharmacolo

41 pse and likely to benefit from a long-acting injectable antipsychotic.

42 Long-acting injectable antipsychotics are used to reduce medication

43 Long-acting injectable antiretroviral (LA-ARV) drugs with low toxici

44 Long-acting injectable antiretroviral agents are being developed for

45 rm (offering intravaginal rings, long-acting injectable antiretroviral drugs) and long term (vaccine,

46 Long-acting injectable antiretrovirals such as rilpivirine (RPV) cou

47 Heparin has been used successfully as an injectable antithrombotic medicine since the 1930s, and

48 ficacy and appropriate treatment duration of injectables are recommended.

49 Accelerate 2), with a switch from quinine to injectable artesunate for management of severe disease a

50 of intracoronary delivery of an innovative, injectable bioabsorbable scaffold (IK-5001), to prevent

51 Here we report novel syringe-injectable bioadhesive hydrogels with inherent antibacte

52 l objective of this study was to engineer an injectable biocompatible hydrogel system as a supportive

53 ideration of additional treatment, including injectable biologic agents.

54 interactions between inflammatory cells and injectable biomaterials can induce beneficial extracellu

55 Injectable biomaterials have shown some promise, althoug

56 Novel injectable biosensors were used to measure interstitial

57 These injectable brachytherapy hydrogels were used to treat tw

58 ed with oral (by 22 655 [24%] of 94 785) and injectable (by 5219 [30%] of 17 684) antimalarial drugs

59 support further investigation of long-acting injectable cabotegravir as an alternative to orally admi

60 rial was undertaken to assess the effects of injectable ceftiofur crystalline-free acid (CCFA) versus

61 t is difficult to achieve minimally invasive injectable cell delivery while maintaining high cell ret

62 e CGRP pathway and the possibility that this injectable CGRP analogue may be effective in cardiac dis

63 Combined injectable chemical and inhalation restraint provided a

64 With injectable chemical restraint alone, spontaneous fluctua

65 Here, we introduce an injectable class of cellular-scale optoelectronics that

66 een depot medroxyprogesterone acetate (DMPA) injectable contraception and the prevalence of periodont

67 epo-medroxyprogesterone acetate (DMPA) is an injectable contraceptive that contains the same progesti

68 6832 to 4708 (relative reduction, 31.1%) for injectable contraceptives (P<0.001 for both comparisons)

69 alth Agents (CBRHAs) were trained to provide injectable contraceptives and were provided with a loan

70 Among women using injectable contraceptives at baseline, we observed rates

71 o pave the way for community distribution of injectable contraceptives but sustaining such efforts re

72 ceptives and were provided with a loan of 25 injectable contraceptives from a drug revolving fund, cr

73 progesterone acetate (DMPA) or non-specified injectable contraceptives had heterogeneous methods and

74 er proposes a model for increasing access to injectable contraceptives in rural settings by using com

75 Respondents who had ever used injectable contraceptives or who were interested in usin

76 ctable contraceptives, their odds of WTP for injectable contraceptives vary across length of time the

77 omen who work for pay, their odds of WTP for injectable contraceptives vary by whether they agree wit

78 e of the training and 96% believed providing injectable contraceptives would improve their services.

79 Among women using injectable contraceptives, the percentage of women who r

80 Among women who prefer injectable contraceptives, their odds of WTP for injecta

81 For women using injectable contraceptives, there was a reduction in the

82 that could be leveraged to increase WTP for injectable contraceptives.

83 njections, 47% were provided to new users of injectable contraceptives.

84 tainability while increasing rural access to injectable contraceptives.

85 as a promising lead for development as an IM injectable cyanide antidote.

86 potential use of PPS-b-PDMA-b-PNIPAAM as an injectable, cyto-protective hydrogel that overcomes conv

87 n-like unit) with GAG GM-0111, we created an injectable delivery platform that transitioned in <5min

88 biodegradable micromatrix, are suitable for injectable delivery.

89 elastin-like polypeptide (ELP) to create an injectable depot for sustained, local delivery of curcum

90 Biodegradable, injectable depot formulations for long-term controlled d

91 n below body temperature, thereby forming an injectable depot.

92 ure and body temperature, thereby forming an injectable depot.

93 Injectable depots are typically prepared by encapsulatio

94 le production of low-cost controlled-release injectable depots for leuprolide and related peptides.

95 rticipants were randomly assigned to receive injectable diacetylmorphine or hydromorphone (up to 3 ti

96 o prior therapies if BRAF mutant, measurable/injectable disease, and without symptomatic autoimmunity

97 (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advoc

98 ive multiple sclerosis during treatment with injectable disease-modifying therapies, switching to nat

99 Discontinuation of injectable disease-modifying therapy (DMT) for multiple

100 Patients with MS who discontinued injectable DMT after a long period of relapse freedom ha

101 With such large injectable doses of synthetic insulins remaining in the

102 ated the application of MEs as extravascular injectable drug delivery systems for sustained release.

103 ke 'top-down' fine milling of excipient-free injectable drug suspensions are not yet clinically viabl

104 line drug, 20.0% to at least one second-line injectable drug, and 12.9% to at least one fluoroquinolo

105 cquisition of resistance (AR) to second-line injectable drugs (SLIs) or fluoroquinolones (FQs) and mo

106 re associated with resistance to second-line injectable drugs across countries.

107 lisation, the most effective method, towards injectable drugs and barrier methods, might have led to

108 nticancer medications and payment reform for injectable drugs hold promise.

109 or at least fluoroquinolones and second-line injectable drugs, and not having extensively drug-resist

110 eralization capacity and biocompatibility of injectable, dual-gelling hydrogels in a rat cranial defe

111 he tailored mineralization capacity of these injectable, dual-gelling hydrogels with hydrolysis-depen

112 demonstrate several applications of syringe-injectable electronics as a general approach for interpe

113 oidance of antigens and availability of self-injectable epinephrine has been a major focus of researc

114 edness with appropriate prescription of self-injectable epinephrine is important.

115 /=5 episodes), 52% had never received a self-injectable epinephrine prescription, and 60% did not cur

116 mpleting oral immunotherapy and some require injectable epinephrine.

117 Thirteen patients (6.7%) required injectable epinephrine.

118 f a novel 'modular' anesthesia that combined injectable (fentanyl-fluanisone/midazolam) and volatile

119 Herein we report an injectable film by which antibodies can be localized in

120 r detection of LPS in commonly used clinical injectable fluids, and it enables selective detection of

121 optical tissue clearing and a TAM-targeting injectable fluorescent nanoparticle (NP) to examine thre

122 ls, including first-line agents, second-line injectables, fluoroquinolones, and World Health Organiza

123 to present advanced techniques using facial injectables for periocular rejuvenation.

124 In this paper, we describe a microdose-scale injectable formulation of nanoparticles that interrogate

125 ease naltrexone, a sustained-release monthly injectable formulation of the full mu-opioid receptor an

126 90% therapeutic, form completely soluble and injectable formulations in mildly acidic conditions, for

127 edes studies of the assessment of longacting injectable formulations of both drugs as a two-drug regi

128 voided potential risks associated with other injectable formulations.

129 troviral drugs in development as long-acting injectable formulations.

130 one formation in the murine maxilla using an injectable gelatin hydrogel (GH) carrier.

131 ered multifunctional biomaterials comprising injectable gelatin-hydroxyphenylpropionic acid (Gtn-HPA)

132 micin for 7 days (group A, reference group); injectable gentamicin and oral amoxicillin for 7 days (g

133 en oral amoxicillin for 5 days (group C); or injectable gentamicin for 2 days and oral amoxicillin fo

134 (8 mg) or placebo, each in combination with injectable glatiramer acetate 20 mg daily.

135 Overall, the injectable group had a 0.263 (SE = 0.017) survival proba

136 estimates were significantly higher for the injectable group in three of the eleven reaches examined

137 Overall, 379 patients in the injectable group were matched to 148 patients in the fin

138 inuation (HR, 0.55; P=.04) compared with the injectable group.

139 The injectable hormonal contraceptive depo-medroxyprogestero

140 Shear-thinning, injectable hyaluronic acid (HA) hydrogels were formed th

141 the surface of Ad, generating a systemically injectable hybrid system, oAd/DCN/LRP-PEG-NT.

142 An injectable hydrogel derived from decellularized porcine

143 This study evaluated the use of an injectable hydrogel derived from ventricular extracellul

144 iable cell encapsulation, the functionalized injectable hydrogel has the potential for controlled del

145 thelial growth factor (VEGF) delivery via an injectable hydrogel system.

146 The design of injectable hydrogel systems addresses the growing demand

147 uction via a thermogelling and pH-responsive injectable hydrogel.

148 results demonstrate the feasibility of this injectable hydrogel/MP based vaccine system to prevent T

149 This article introduces the properties of injectable hydrogels and summarizes their versatile appl

150 The GA-functionalized injectable hydrogels are also found to contribute signif

151 A number of injectable hydrogels are approved by FDA as surgery seal

152 Lastly, injectable hydrogels as depot formulation were formed by

153 eye therapies is driving the development of injectable hydrogels as new medical devices for controll

154 A promising class of synthetic, injectable hydrogels based upon oligo(ethylene glycol) m

155 Injectable hydrogels can provide a scaffold for in situ

156 s the recent progresses on biodegradable and injectable hydrogels fabricated from natural polymers (c

157 Thermosensitive injectable hydrogels have been used for the delivery of

158 ng protein drugs are often incorporated into injectable hydrogels to minimize their displacement at a

159 Injectable hydrogels with biodegradability have in situ

160 substantial progress has been achieved using injectable hydrogels, some challenging issues must still

161 ovides evidence to suggest noninferiority of injectable hydromorphone relative to diacetylmorphine fo

162 Injectable hydrophobic drugs are typically dissolved in

163 set of demyelination, without the need of an injectable immunogen.

164 Switching from injectable immunomodulators to fingolimod is associated

165 who were switching therapy to fingolimod or injectable immunomodulators up to 12 months after on-tre

166 n to objectively select the most appropriate injectable implant depending on the specific anatomical

167 are the factors to consider when choosing an injectable implant.

168 sent novel and advanced techniques utilizing injectables in the periocular region.

169 s a non-invasive alternative to subcutaneous injectable insulin for adults with type 1 or 2 diabetes.

170 because they are unwilling or unable to use injectable insulin.

171 s shortcoming can be circumvented through an injectable, interconnected microporous gel scaffold asse

172 netic coil antennas connected to microscale, injectable light-emitting diodes (LEDs), with the abilit

173 The injectable long-acting formulation of rilpivirine (TMC27

174 ERPRETATION: The two-drug combination of all-injectable, long-acting cabotegravir plus rilpivirine ev

175 Injectable lymphatic tracers have been developed, but th

176 Injectable Magnetic Resonance Imaging (MRI) contrast age

177 No injectable malaria vaccine has demonstrated long-term pr

178 particular, we demonstrate their utility as injectable materials for pipeline maintenance and produc

179 However, the majority of injectable materials gel rapidly upon mixing and/or heat

180 d, including gels, films, vaginal rings, and injectable medication.

181 As) in 2011 appear to have influenced use of injectable medications among dialysis patients.

182 ives to increase home dialysis use: bundling injectable medications into a single payment for treatme

183 Patients with injectable melanoma that was not surgically resectable w

184 The key challenges in the development of injectable mesoporous silica formulations are colloidal

185 cific behaviors, such as the use of condoms, injectable methods or permanent sterilization.

186 ared: preformed cylindrical plugs, preformed injectable microbeads, and hydrogel precursor, injected

187 Recently demonstrated technologies based on injectable, microscale inorganic light-emitting diodes (

188 These findings suggest that injectable MSRs may serve as a multifunctional vaccine p

189 NP absorption, including dermal and medical injectables, must be studied in order to understand poss

190 For injectable naltrexone, meta-analyses found no associatio

191 t commonly used approach to preparing stable injectable nano formulations.

192 Here we report an injectable nanoparticle generator (iNPG) that overcomes

193 Here, we report an injectable nanoparticle-based internal radiation source

194 ated that delivery of MSCs and EPCs with the injectable nCS/A scaffold did not affect cell viability.

195 d using laser and energy devices, as well as injectable neurotoxins and soft-tissue augmentation mate

196 f the three studies that assessed the use of injectable norethisterone enanthate showed a significant

197 R, 0.58; 95% CI, 0.52-0.65), and long-acting injectable olanzapine (HR, 0.58; 95% CI, 0.44-0.77) comp

198 whether patients filled any alternate oral, injectable, or infusible anticancer agent within 90 days

199 after accounting for use of alternate oral, injectable, or infusible anticancer agents.

200 ecular design that provides an intravenously injectable organic radical contrast agent (ORCA) for whi

201 ng monotherapy with once-monthly long-acting injectable paliperidone (hazard ratio [HR], 0.51; 95% CI

202 (SANP) drug delivery system was prepared for injectable passive lung targeting.

203 ical trials, but once daily, next-generation injectable peptide fusion inhibitors have entered human

204 sults show that this fully biocompatible and injectable peptide hydrogel system may be used for contr

205 e (HR, 0.53; 95% CI, 0.48-0.58), long-acting injectable perphenazine (HR, 0.58; 95% CI, 0.52-0.65), a

206 describe key concepts in the development of injectable PLGA controlled-release depots for peptides a

207 d by linking the protein to an insoluble but injectable polymer via a light cleaved linker.

208 unity to combine the best of both classes of injectable polymeric depots.

209 sive material for contrast generation and an injectable polymeric matrix for structural support.

210 vehicle can be further simplified utilizing injectable polymeric nanocarriers coated with RBC membra

211 Injectable polymeric nanoparticles and microparticles ca

212 overcome by the introduction of long-acting injectable PrEP agents, which may be administered monthl

213 However, the cost-effectiveness of injectable PrEP is unclear.

214 Long-acting injectable PrEP, which is in development, may be associa

215 rsistence compared with switching to another injectable preparation following on-treatment activity o

216 We assigned 1170 infants to receive injectable procaine benzylpenicillin-gentamicin and 1163

217 of severe infection was as efficacious as an injectable procaine benzylpenicillin-gentamicin combinat

218 n and oral amoxicillin for 7 days (group B); injectable procaine benzylpenicillin-gentamicin for 2 da

219 ree simplified regimens were as effective as injectable procaine benzylpenicillin-gentamicin for 7 da

220 We randomly allocated infants to receive injectable procaine benzylpenicillin-gentamicin for 7 da

221 e to treatment and adequate follow-up in the injectable procaine benzylpenicillin-gentamicin group an

222 cept referral to hospital, to receive either injectable procaine benzylpenicillin-gentamicin once per

223 gns, is as efficacious as the combination of injectable procaine benzylpenicillin-gentamicin.

224 The first long-acting injectable product (Depo-Provera(R)) was approved in the

225 ere is concern that high-dose, long-lasting, injectable progestin-based contraception could mimic the

226 Injectable progestin-only contraceptive use and high end

227 sition risk, including those associated with injectable progestin-only contraceptive use.

228 HIV-negative injectable progestin-only contraceptive users had 3.92 t

229 The use of injectable progestin-only contraceptives has been associ

230 Women using injectable progestin-only contraceptives were at substan

231 In this cohort, 152 women used injectable progestin-only contraceptives, 43 used other

232 n state had similar immunological effects to injectable progestin-only contraceptives.

233 hormonal contraception", "HIV/acquisition", "injectables", "progestin", and "oral contraceptive pills

234 g combined oral contraceptives (COCs) or the injectable progestins depot-medroxyprogesterone acetate

235 ssembly of polymer Layers (SEAL), and create injectable pulsatile drug-delivery microparticles, pH se

236 t in situ self-assembly of biodegradable and injectable radionuclide-containing polypeptide seeds cou

237 Here we present an injectable reconstituted high-density lipoprotein (rHDL)

238 -resistant multidrug resistance, second-line injectable-resistant multidrug resistance, and extensive

239 The use of long-acting injectable risperidone after a first episode of schizoph

240 Long-acting injectable risperidone better controlled mean levels of

241 ized, 3 refused treatment in the long-acting injectable risperidone group.

242 renia were randomized to receive long-acting injectable risperidone or oral risperidone.

243 okine responses equipotent with conventional injectable routes of immunization.

244 nd tunable release of a peptide drug from an injectable s.c. depot.

245 A novel injectable saRNA-oligonucleotide that enhances C/EBPalph

246 les for MSC delivery are a biodegradable and injectable scaffold that can be used for clinical applic

247 s review on bioactive nanofibrous scaffolds, injectable scaffolds and stem cells, and pre-clinical fi

248 These injectable scaffolds show great promise for various biom

249 Long-acting, injectable, second-generation antipsychotic medication h

250 ng histamine levels in vivo using a modular, injectable sensing platform based on diamine oxidase and

251 risk factors for acquired resistance (AR) to injectable SLDs (INJ SLDs) and fluoroquinolones in the U

252 essary to transform the frozen solid into an injectable solution containing the hyperpolarized (13)C-

253 at has been formulated as a long-acting (LA) injectable suitable for monthly to quarterly clinical ad

254 oroidal injection of triamcinolone acetonide injectable suspension (CLS-TA), in eyes with macular ede

255 Together, the LFA and injectable synthetic biomarkers, which could be tailored

256 , we developed a treatment strategy using an injectable system with photo-cross-linkable hydrogel (G)

257 f-assembling type I collagen oligomers as an injectable therapeutic delivery vehicle in mice.

258 ity, EndoS is being developed as a promising injectable therapeutic for autoimmune diseases that rely

259 Peptide hormones are attractive as injectable therapeutics and imaging agents, but they oft

260 ) have expanded in recent years, and several injectable therapies are under development.

261 In this Rapid Review, we summarise emerging injectable therapies for relapsing-remitting MS, and dis

262 Patients need only have remained on injectable therapy for 1 day and were monitored on any a

263 se, we defined baseline as the date of first injectable therapy initiation.

264 ients with type 2 diabetes start their first injectable therapy, clinicians can choose between glucag

265 lin glargine (henceforth, glargine) as first injectable therapy.

266 OPF hydrogels are injectable, they polymerize in situ and they undergo bio

267 perties is that the microfiber suspension is injectable through a needle, from which it can be extrud

268 activity and mechanism of action of a novel, injectable, tissue-retained TLR7/8 agonist, 3M-052, whic

269 lications such as drug delivery, macroscopic injectables, tissue-engineering scaffolds, and nano-imag

270 conducted to evaluate the performance of the injectable transmitter and its effect on the survival of

271 ing Chinook salmon smolts implanted with the injectable transmitter had a higher survival probability

272 The newly developed injectable transmitter is the first acoustic transmitter

273 The injectable transmitter performed well and similarly to t

274 eceptor agonists could be a viable long-term injectable treatment option in patients with type 2 diab

275 is about 20% to 30% lower during long-acting injectable treatments compared with equivalent oral form

276 t dosing than currently available first-line injectable treatments.

277 ex) and being amenorrhoeic (due to progestin-injectable use), but not recent vaginal cleansing, were

278 iation with recent vaginal sex and progestin-injectable use.

279 requency of cosmetic dermatology devices and injectables used for dermatology resident hands-on cosme

280 Access to injectable uterotonics for management of postpartum haem

281 nowledge, attitudes, and practices regarding injectable vaccine administration.

282 Following the licensing of an injectable vaccine, we consider the relative merits of m

283 V shortages (20%), hesitancy to administer 2 injectable vaccines (28%), lack of knowledge on multi-do

284 f IPV would necessitate delivery of multiple injectable vaccines (hereafter, "multiple injections") d

285 ) of which adopted a schedule resulting in 3 injectable vaccines being administered in a single visit

286 the same facilities to explore the number of injectable vaccines children received during their 2- an

287 ries) to determine coverage of the following injectable vaccines delivered through the routine immuni

288 increasing the maximum recommended number of injectable vaccines given in a single visit from 2 to 3.

289 f of caregivers whose children got 3 or more injectable vaccines in a single visit reported being onl

290 tation regarding children receiving multiple injectable vaccines in a single visit, most children rec

291 reported being only comfortable with 1 or 2 injectable vaccines in a single visit.

292 or 4-month immunization visit received all 3 injectable vaccines in a single visit.

293 cancer therapy have been based generally on injectable vector systems used to control foreign infect

294 The relative effectiveness of long-acting injectable versions of second-generation and older antip

295 Here, by developing injectable, void-forming hydrogels that decouple pore fo

296 A 12-month trial comparing the long-acting injectable vs oral risperidone and cognitive remediation

297 An injectable with low viscosity may be ideal for lip enhan

298 to both a fluoroquinolone and a second-line injectable (XDR).

299 gnition of the recent nationwide shortage of injectable zinc available for total parenteral nutrition

300 [HR], 0.51; 95% CI, 0.41-0.64), long-acting injectable zuclopenthixol (HR, 0.53; 95% CI, 0.48-0.57),